Skip to content

Nano-X Image Guidance: CBCT With Gravity-induced Motion

Nano-X Image Guidance: CBCT With Gravity-induced Motion

Status
Withdrawn
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04488224
Acronym
Nano-X IG
Enrollment
0
Registered
2020-07-27
Start date
2025-09-01
Completion date
2025-12-11
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Radiation Therapy, Image Guidance

Brief summary

A pilot stage, device feasibility trial, to investigate the feasibility of acquiring cone beam computed tomography (CBCT) images for image guidance for radiation therapy by maintaining a fixed imaging system and rotating the participant about the horizontal axis using the Nano-X patient rotation system. It is a single-arm, controlled, single-blinded, non-treatment, non-invasive, single-institution trial.

Detailed description

Primary objective: To investigate the feasibility of volumetric image guidance for the Nano-X patient rotation system (PRS). Secondary objectives: 1. To develop image reconstruction methods that allow target and normal tissue visualisation at all treatment angles to a clinical cone beam computed tomography (CBCT) standard. 2. To determine the reproducibility and variability in Nano-X CBCT compared to clinical CBCT. 3. To measure the magnitude of gravity-induced anatomical deformation and translation. 4. To develop treatment plan adaptation methods to compensate for gravity-induced target motion based on Nano-X CBCT image reconstruction at varying treatment angles. 5. To quantify the participant experience of horizontal rotation using the Nano-X PRS for volumetric image guidance CBCT acquisition. The investigators will perform a pilot stage, device feasibility trial, to investigate the feasibility of acquiring CBCT images for image guidance by maintaining a fixed imaging system and rotating the participant about the horizontal axis using the Nano-X PRS. It is a single-arm, controlled, single-blinded, non-treatment, non-invasive, single-institution trial. Eligible participants will be asked to attend the Nelune Comprehensive Cancer Centre (NCCC) at the Prince of Wales Hospital on two separate occasions to obtain Nano-X CBCT scans. For each scan the participant will be rotated 360° about the horizontal axis which will take approximately 72 seconds to complete. Participants will be asked to complete validated psychometric questionnaires before and after each Nano-X CBCT. The questionnaire responses will be used to quantify their experiences of anxiety and motion sickness, and report previous experiences of claustrophobia, in order to identify determinants of tolerance level. The projection data sets from the Nano-X CBCT scans, along with conventional CBCTs obtained for the participants' standard radiotherapy treatment, will be used to investigate the image-related objectives. The two Nano-X CBCT data sets from each participant will be used to compare Nano-X CBCT variability and reproducibility to clinical CBCT acquisition.

Interventions

DEVICENano-X Patient Rotation System

The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis. This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired.

RADIATIONConventional CBCT scan

A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.

OTHERPsychometrically validated questionnaires

The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.

Sponsors

University of Sydney
Lead SponsorOTHER
South Eastern Sydney Local Health District
CollaboratorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DEVICE_FEASIBILITY
Masking
SINGLE (Outcomes Assessor)

Masking description

The Postdoctoral Research Associate will collect and de-identify CBCT images acquired during Nano-X rotation session and during participants' routine treatment. The software used to display the scans will incorporate a random number generator to determine the labeling of images as 'A' or 'B'. Observers assessing image quality for study outcomes will be masked to the source of either image.

Intervention model description

All participants will undergo CBCT imaging during rotation on the Nano-X patient rotation system. For each participant, quality of CBCT images acquired during the rotation session will be compared with quality of CBCT images collected during their standard radiation therapy treatment.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Cancer patients that are receiving radiation therapy that are able to be imaged with the Nano-X PRS with one of the following tumour sites: 1. in the head/neck region 2. in the chest/abdomen/pelvic region with fast CBCT used for standard of care image guidance and is aged 60 years or older 3. in the chest/abdomen/pelvic region not receiving CBCT for standard of care image guidance and is aged 70 years or older 4. diagnosis of lung cancer with stage II-IV 2. ≥18 years of age 3. ECOG Performance Status 0-2 4. Must be able to communicate fluently in English to: i. Receive instructions from operators of the PRS for safety entering and leaving the Patient Rotation System and required conduct during the during the rotation session, and ii. Communicate their level of comfort or distress to operators of the equipment. 5. Signed, written informed consent or approved alternative, non-contact method for informed consent.

Exclusion criteria

1. Pregnant women 2. Patients for whom attaining informed consent would not be possible, including mentally impairment 3. Patients with severe vertigo or recent a diagnosis of Benign Paroxysmal Positioning Vertigo.

Design outcomes

Primary

MeasureTime frameDescription
Number of Cone Beam Computed Tomography (CBCT) images acquired with horizontal patient rotation that are deemed to be of comparable image quality to clinical CBCT or deemed acceptable for radiotherapy image guidance as scored by a panel of experts.6 monthsObservers will view the image sets in 3 orthogonal views and grade the image quality considering geometrical accuracy, anatomical visualisation, sharpness of the image, soft tissue contrast, image noise and uniformity and overall clinical usability. The imaging method will be deemed technically feasible if \>70% of CBCT images acquired with horizontal patient rotation are deemed of clinical quality.

Secondary

MeasureTime frameDescription
Change in Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaire scores before and after rotation as assessed by the Wilcoxon signed rank test.6 monthsWilcoxon signed rank test used to determine statistically significant differences in anxiety and motion sickness assessed using psychometrically validated surveys completed prior to and post horizontal rotation CBCT scan. The STAI questionnaire is used to assess anxiety and is comprised of 6 questions scored 1-4. These are combined for a final score between 6 and 24, where a higher number indicates a greater level of anxiety. The FMS questionnaire is used to assess motion sickness. Participants rate their levels of motion sickness on a scale of 0-20 where 0 is no feeling of nausea and 20 is feeling terrible and very sick.

Contacts

PRINCIPAL_INVESTIGATORPaul J Keall, PhD

ACRF Image X Institute, University of Sydney

PRINCIPAL_INVESTIGATORMichael Jackson, MD

Prince of Wales Hospital

STUDY_CHAIRSimon Downes, MASc

Prince of Wales Hospital

STUDY_CHAIRMark Gardner, PhD

ACRF Image X Institute, University of Sydney

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026